Preclinical data showed promise in both systemic sclerosis bleomycin-induced mouse models and in patient-derived skin fibroblasts treated with EYD-001. The Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results